<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682288</url>
  </required_header>
  <id_info>
    <org_study_id>LEVO-CS101</org_study_id>
    <nct_id>NCT04682288</nct_id>
  </id_info>
  <brief_title>Levofloxacin Ocular Implant for Ocular Surgery</brief_title>
  <official_title>An Interventional, Open Label, Non-randomized, Phase Ia Safety and Tolerability Study of Levofloxacin Ocular Implant in Subjects Undergoing Routine Cataract Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PolyActiva Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PolyActiva Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi center, open label, interventional study in one eye of 5 subjects scheduled&#xD;
      for uncomplicated cataract surgery with administration of a single Levofloxacin Ocular&#xD;
      Implant in the posterior sulcus of the surgical eye at the end of cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Inflammation</measure>
    <time_frame>90 days</time_frame>
    <description>Change assessed according to Standardization of Uveitis Nomenclature (SUN) Grading Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial Cell Density</measure>
    <time_frame>90 days</time_frame>
    <description>Change in number of central corneal endothelial cells per mm2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>90 days</time_frame>
    <description>Change in IOP measured by Goldmann applenation tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Administration procedure</measure>
    <time_frame>1 week</time_frame>
    <description>Number of actuation's required to expel implant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Levofloxacin Ocular Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biphasic levofloxacin antibiotic implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin Ocular Implant</intervention_name>
    <description>Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.</description>
    <arm_group_label>Levofloxacin Ocular Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cataract in the intent to treat eye&#xD;
&#xD;
          -  Endothelial cell density in the study eye of at least 2000 cells per mm2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of ocular inflammation including, macular degeneration, uveitis, macular edema&#xD;
             or corneal edema&#xD;
&#xD;
          -  recent surgery in the study eye&#xD;
&#xD;
          -  subjects receiving a glaucoma device in conjunction with cataract surgery&#xD;
&#xD;
          -  subjects with a compromised posterior capsule during surgery&#xD;
&#xD;
          -  corneal disease that prevents effective imaging of endothelium including Fuch's&#xD;
             Dystrophy.&#xD;
&#xD;
          -  sensitivity to fluoroquinolones&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Gira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Opthalmology Consultants Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Russell Tait</last_name>
    <phone>+61396570700</phone>
    <email>russell.tait@polyactiva.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ophthalmology Consultants Ltd</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Cataract and Laser Centre</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melbourne Eye Specialists</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

